NDA 214012 · Novartis
Leqvio
Inclisiran Sodium · Subcutaneous
NovelOrphanCDER novel approval, Dec 22, 2021: To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapy
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 22, 2021
Approved uses
4
Original approval plus efficacy supplements
Registered trials
56
24 Phase 3, 17 recruiting
FAERS reports
8,446
3,638 serious, 238 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 19, 2026.
LEQVIO ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy. LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. ( 1 ) adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). ( 1 ) Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy. ( 1 )
Mechanism: Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 12, 2026 Supplement 18 · Efficacy · priority review OrphanLetterLabel
- Feb 12, 2026 Supplement 17 · Efficacy · priority review LetterLabel
- Jul 31, 2025 Supplement 16 · Efficacy LetterLabel
- Dec 22, 2021 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- LEQVIO · INCLISIRAN SODIUM EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Inclisiran" as an intervention, any sponsor and status, largest first.
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseasePivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05030428 · 17,004 participants · Start Nov 23, 2021 · Primary completion May 10, 2027
Drug: Inclisiran sodium 300 mg; Placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 989 sites in all
- A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular DiseasePivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT03705234 · 16,124 participants · Start Oct 30, 2018 · Primary completion Oct 2026
Drug: Inclisiran; Placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Boston, Massachusetts; Oxford, United Kingdom
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05739383 · 14,012 participants · Start Mar 9, 2023 · Primary completion Apr 16, 2029
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Placebo in 1.5ml · For: Primary Prevention of Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 983 sites in all
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionPivotal-lookingRecruiting
Duke UniversityAcademic, hospital or other
NCT06909565 · 6,000 participants (planned) · Start Jul 23, 2025 · Primary completion Oct 2029
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Normal Saline (Placebo) · For: Percutaneous Coronary Intervention; Peripheral Endovascular Intervention
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 153 sites in all
- Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-CPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03814187 · 3,275 participants · Start Apr 16, 2019 · Primary completion Feb 13, 2023
Drug: Inclisiran Sodium · For: ASCVD; Elevated Cholesterol; Heterozygous Familial Hypercholesterolemia and 1 more
Sites: Birmingham, Alabama; Foley, Alabama; Huntsville, Alabama · 238 sites in all
- Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With HypercholesterolemiaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05192941 · 1,770 participants · Start Apr 8, 2022 · Primary completion Jun 11, 2024
Drug: Inclisiran Sodium; Placebo · For: Hypercholesterolemia
Sites: Sofia, Bulgaria; Burgas, Bulgaria; Gabrovo, Bulgaria · 136 sites in all
- Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein CholesterolPivotal-lookingCompleted
The Medicines CompanyIndustry
NCT03400800 · 1,617 participants · Start Nov 1, 2017 · Primary completion Jul 31, 2019
Drug: Inclisiran Sodium; Placebo · For: ASCVD; Risk Factor, Cardiovascular; Elevated Cholesterol
Sites: Chomutov, Czechia; Uherské Hradiště, Czechia; Berlin, Germany · 70 sites in all
- The Prevent Coronary Artery Disease TrialPivotal-lookingRecruiting
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT06494501 · 1,600 participants (planned) · Start Sep 12, 2024 · Primary completion Jun 30, 2032
Drug: Inclisiran · For: Atherosclerotic Cardiovascular Disease
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- arthralgia908
- myalgia706
- injection site pain600
- low density lipoprotein increased529
- pain in extremity510
- drug ineffective442
- fatigue440
- pain423
- diarrhoea389
- dyspnoea375
- headache330
- rash299
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 32 |
| 2022 | 910 |
| 2023 | 2,224 |
| 2024 | 1,909 |
| 2025 | 1,933 |
| 2026 | 1,435 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Leqvio (Inclisiran Sodium)
2024 spending
$14.4M
Beneficiaries
2,681
4,425 claims
Per beneficiary
$5,364
$2,162.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $3,796,981 |
| 2023 | $10,564,892 |
| 2024 | $14,379,723 |
Part B: Leqvio (Inclisiran Sodium) · HCPCS J1306
2024 spending
$296M
Beneficiaries
48,298
87,716 claims
Per beneficiary
$6,135
2024 ASP limit $12.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $28,475,760 |
| 2023 | $143,175,005 |
| 2024 | $296,288,761 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK, Wright RS, Kallend D, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
Wright RS, Raal FJ, Koenig W, et al. · Cardiovasc Res 2024 · Multicenter Study, Clinical Trial, Phase III
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ, Kallend D, Ray KK, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK, Landmesser U, Leiter LA, et al. · N Engl J Med 2017 · Clinical Trial, Phase II, Multicenter Study
- Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial.
Landmesser U, Laufs U, Schatz U, et al. · Eur Heart J 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis.
Zhang S, Sun L, Xu X, et al. · BMC Cardiovasc Disord 2024 · Comparative Study, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.